Stay updated with breaking news from Extension Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3...
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial...
11.05.2023 - - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical ...
ALPHARETTA, Ga., April 27, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ,... | April 27, 2023
- Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga.,...